Free Trial
→ The Iran War Isn’t Chaos. It’s Strategy. (From Behind the Markets) (Ad)tc pixel
NASDAQ:ORGS

Orgenesis Earnings Date & Estimates

Orgenesis logo
$0.35 +0.28 (+400.00%)
As of 11:07 AM Eastern

Orgenesis is estimated to report earnings on Wednesday, November 11, 2026.

Research:Profile

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Orgenesis

Orgenesis is expected to post earnings of -$2.60 per share on revenue of $2.80 million.

Consensus Estimates

Consensus EPS
-$2.60
Expected Revenue
$2.80 million

Recent Track Record

Last Reported
Q2 2024
Last Quarter EPS
-$2.30
Last Quarter Revenue
$0.25 million

Prepare for the Earnings Call

Orgenesis Earnings FAQ

Orgenesis (NASDAQ:ORGS) is estimated to report earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Orgenesis to post earnings of -$2.60 per share for the quarter.

The consensus revenue estimate for Orgenesis is $2.80 million for the quarter.

Orgenesis Earnings Headlines

Orgenesis (NASDAQ:ORGS) Stock Falls 5.2% - Here's What Happened
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31089949
Orgenesis Shareholders Approve Major Charter and Stock Increase
June 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ORGS/pressreleases/2292841/orgenesis-shareholders-approve-major-charter-and-stock-increase/
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.tc pixel
October 14 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Orgenesis Issues Alpha Warrant in New Financing Deal
January 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/orgenesis-issues-alpha-warrant-in-new-financing-deal?utm_source=marketbeat.com&utm_medium=referral
Orgenesis Subsidiary Secures Convertible Loan Agreement
September 16, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/orgenesis-subsidiary-secures-convertible-loan-agreement?utm_source=marketbeat.com&utm_medium=referral
Orgenesis Director Ashish Nanda Resigns
August 25, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/orgenesis-director-ashish-nanda-resigns?utm_source=marketbeat.com&utm_medium=referral
See More Orgenesis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orgenesis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orgenesis and other key companies, straight to your email.

About Orgenesis

Orgenesis (NASDAQ:ORGS) is a biotechnology company focused on developing and enabling cell and gene therapies. The company works on autologous cell therapies, which use a patient’s own cells, and on technologies designed to support the processing, manufacturing and delivery of these therapies.

Its activities include the development of proprietary therapeutic programs and the Orgenesis POCare platform. POCare is intended to provide decentralized, point-of-care capabilities for cell and gene therapy manufacturing, helping clinical and healthcare sites produce treatments closer to the patient under controlled processes.

Orgenesis was founded in 2011 and has pursued partnerships and operations across the United States, Europe and Israel. Vered Caplan, a co-founder of the company, has served as its chief executive officer. The company’s work combines therapeutic development with manufacturing infrastructure intended to support broader adoption of advanced cell and gene therapies.

View Orgenesis Profile
Earnings Tools